Photo from wikipedia
The trial assigning individualized options for treatment (Rx) (TAILORx) confirmed the predictive value of the 21‐gene recurrence score (RS) assay in hormone receptor (HR)–positive, HER2‐negative, node‐negative breast cancer and established… Click to show full abstract
The trial assigning individualized options for treatment (Rx) (TAILORx) confirmed the predictive value of the 21‐gene recurrence score (RS) assay in hormone receptor (HR)–positive, HER2‐negative, node‐negative breast cancer and established thresholds for chemotherapy benefit in younger and older patients. Real‐world chemotherapy use and RS‐guided treatment costs in British Columbia post‐TAILORx were examined.
Keywords:
cancer;
breast cancer;
guided treatment;
treatment;
recurrence score;
gene recurrence
Journal Title: Cancer
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!